KickStart Venture Services’ Post

🔬🌱 CER Groupe Shares Preclinical and Biomanufacturing Expertise with Master 2 of Biochemistry and Molecular and Cell Biology at University of Namur. Recently, Tania Durré and Riccardo Marega had the privilege of hosting a thought-provoking seminar at the esteemed UNamur - Recherche, upon invitation by Florence Chainiaux (FNRS research associate ). The session, titled "Exploring the Potential of Preclinical Biomanufacturing and Analytical through the Use of Mammalian Cells: Perspectives of the CER Groupe," was designed to engage and enlighten Master 2 students of Biochemistry and Molecular and Cell Biology. Over the course of two enriching hours, we delved into the invaluable insights offered by mammalian cells, focusing on the intricate world of biomanufacturing and preclinical studies. It was truly inspiring to witness the enthusiasm and curiosity of the students, as they actively participated in stimulating discussions and posed insightful questions. At CER Groupe, we are deeply committed to fostering knowledge exchange and nurturing the next generation of scientific leaders. Our seminar not only provided a platform for sharing expertise but also served as a catalyst for igniting passion and curiosity in the realm of biotechnology. We extend our heartfelt gratitude to #UNamur for hosting us and to the Master 2 students of Biochemistry and Molecular and Cell Biology for their active engagement. Together, we are paving the way for innovative advancements in the field of biomanufacturing and analytical sciences. Stay tuned for more exciting updates and collaborative opportunities ahead! #Biotechnology #ScienceEducation #CERGroupe #UniversityCollaboration #Knowledge #Biochemistry #Preclinical #Biomanufacturing

The SPARK translational research model is featured in the February 2024 issue of Nature Biotechnology in an article authored by a team that includes its creators and SPARK NS staff members. "Over the past 17 years, SPARK at Stanford has a ~50% success rate as measured by two criteria: advancing projects through licensing to commercial entities and/or entering into investigator-initiated clinical studies.” Read the story behind the development and refinement of this very successful approach to translational research at Stanford and elsewhere here: https://rdcu.be/dyJug

We have adopted the SPARK translational research model for drug development to advance academic discoveries in neuroscience. The SPARK model was developed at Stanford University and, over the past 17 years, has produced a ~50% success rate as measured by two criteria: advancing projects through licensing to commercial entities and/or entering into investigator-initiated clinical studies. Learn more about the SPARK model in the latest issue of Nature Biotechnology https://lnkd.in/gV4bWQYZ

41 exceptional Nordic researchers have just received a Novo Nordisk Foundation career grant (for at total amount of EUR 57.3 million). The researchers work across a broad spectrum of scientific disciplines. The recipients represent a diverse range of institutions from all the Nordic countries, including for instance Aalborg University Hospital, Syddansk Universitet - University of Southern Denmark, Karolinska Institutet Institute, University of Helsinki, Danish Cancer Society and Københavns Universitet - University of Copenhagen. The Novo Nordisk Foundation Research Leader Programme aims to support researchers at various stages of their careers, providing them with the necessary resources to conduct groundbreaking research. Since 2018, more than 240 researchers have received grants for a total of nearly EUR 400 million. The 2024-grants cover five key research areas: - Endocrinology and Metabolism Research: 10 grants. - Clinical and Translational Research: 10 grants. - Bioscience and Basic Biomedical Research: 13 grants. - Plant Science, Agriculture and Food Biotechnology: 4 grants. - Industrial Biotechnology and Environmental Biotechnology: 4 grants. Our programme offers grants tailored to different career stages: - Emerging Investigator: For researchers establishing their research groups. - Ascending Investigator: For associate professors consolidating their research profiles. - Distinguished Investigator: For internationally recognised professors. Read more about each of this year’s grant recipients as well as previous years’ recipients at the Research Leader Programme website: https://lnkd.in/d9pCxptg. Read more about the impact of the Novo Nordisk Foundation's support to science in our new annual impact report: https://lnkd.in/dDjx9qzP

Looking forward to participating with my talk on AI in medical imaging.

🔎🔎🔎 𝐌𝐞𝐞𝐭 Thomas Colson – 𝐅𝐍𝐑𝐒 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐟𝐞𝐥𝐥𝐨𝐰 - 𝐀𝐒𝐏 🔍🔍🔍 🏫 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲 : Laboratory of Medicinal Chemistry 🎓 𝐒𝐮𝐩𝐞𝐫𝐯𝐢𝐬𝐨𝐫 : 𝐏𝐫𝐨𝐟. Pierre Francotte 𝐞𝐭 𝐏𝐫𝐨𝐟. 𝐁𝐞𝐫𝐧𝐚𝐫𝐝 𝐏𝐢𝐫𝐨𝐭𝐭𝐞 🔬 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 : "Rational design of selective positive allosteric modulators of kainate receptors" 👨🔬 𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 : 𝑇ℎ𝑒 𝑔𝑜𝑎𝑙 𝑜𝑓 𝑡ℎ𝑖𝑠 𝑝𝑟𝑜𝑗𝑒𝑐𝑡 𝑖𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑛𝑒𝑤 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑡ℎ𝑎𝑡 𝑒𝑛ℎ𝑎𝑛𝑐𝑒 𝑡ℎ𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑘𝑎𝑖𝑛𝑖𝑐 𝑎𝑐𝑖𝑑-𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟𝑠 (𝐾𝐴𝑅𝑠) 𝑖𝑛 𝑡ℎ𝑒 𝑏𝑟𝑎𝑖𝑛, 𝑤ℎ𝑖𝑐ℎ 𝑝𝑙𝑎𝑦 𝑎 𝑐𝑟𝑢𝑐𝑖𝑎𝑙 𝑟𝑜𝑙𝑒 𝑖𝑛 𝑛𝑒𝑟𝑣𝑒 𝑠𝑖𝑔𝑛𝑎𝑙 𝑡𝑟𝑎𝑛𝑠𝑚𝑖𝑠𝑠𝑖𝑜𝑛. 𝐵𝑦 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑖𝑛𝑔 𝑡ℎ𝑒𝑠𝑒 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟𝑠, 𝑖𝑡 𝑚𝑎𝑦 𝑏𝑒 𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒 𝑡𝑜 𝑡𝑟𝑒𝑎𝑡 𝑛𝑒𝑢𝑟𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑘𝑒 𝑒𝑝𝑖𝑙𝑒𝑝𝑠𝑦, 𝑐ℎ𝑟𝑜𝑛𝑖𝑐 𝑝𝑎𝑖𝑛, 𝑚𝑜𝑜𝑑 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟𝑠, 𝑎𝑛𝑑 𝑐𝑜𝑔𝑛𝑖𝑡𝑖𝑣𝑒 𝑖𝑠𝑠𝑢𝑒𝑠 𝑠𝑢𝑐ℎ 𝑎𝑠 𝐴𝑙𝑧ℎ𝑒𝑖𝑚𝑒𝑟'𝑠 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 (𝐷𝑒𝑒𝑝𝑎 𝑒𝑡 𝑎𝑙., 2023). 𝑈𝑠𝑖𝑛𝑔 𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑜𝑔𝑟𝑎𝑝ℎ𝑦 𝑡𝑜 𝑎𝑛𝑎𝑙𝑦𝑧𝑒 𝑙𝑖𝑔𝑎𝑛𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑠 𝑎𝑛𝑑 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑝𝑜𝑐𝑘𝑒𝑡𝑠, 𝑤𝑒 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑦 𝑖𝑑𝑒𝑎𝑙 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑠 𝑓𝑜𝑟 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑏𝑖𝑛𝑑𝑖𝑛𝑔. 𝑇ℎ𝑒 𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑧𝑒𝑑 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑎𝑟𝑒 𝑡ℎ𝑒𝑛 𝑒𝑣𝑎𝑙𝑢𝑎𝑡𝑒𝑑 𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 𝑡𝑜 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑎𝑛𝑑 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒-𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛𝑠ℎ𝑖𝑝𝑠, 𝑎𝑖𝑚𝑖𝑛𝑔 𝑡𝑜 𝑟𝑒𝑓𝑖𝑛𝑒 𝑡ℎ𝑒 𝑓𝑖𝑛𝑎𝑙 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒 𝑓𝑜𝑟 𝑎 𝑝𝑟𝑜𝑚𝑖𝑠𝑖𝑛𝑔 𝑑𝑟𝑢𝑔 𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒. 🌟 𝐎𝐭𝐡𝐞𝐫 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 : • Global Coordinator of the “CIRM Young Scientists Committee” 📚 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫'𝐬 𝐁𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝 : 2017: Obtained the CNaVT from KULeuven 2020: Bachelor's degree in Pharmaceutical Sciences (Distinction), ULiège 2021: Research Student Status for the Léon Frédéricq Foundation 2022: Master's degree in Pharmaceutical Sciences, specialized in Drug Design and Development - Bioanalysis (Highest Distinction), ULiège 2022: Doctoral training in Biomedical and Pharmaceutical Sciences. 💡 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 : https://lnkd.in/edN8mmzk 🎭🎉𝐏𝐚𝐬𝐬𝐢𝐨𝐧𝐬 : I’m passionate about history and geopolitics. However, my main passion is running. I constantly train to improve my performance in my favorite distances: the half-marathon and the marathon. 📝 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐮𝐫 𝐩𝐚𝐠𝐞 𝐭𝐨 𝐬𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬!

🔔 Deadline Extended! 🔔 We've extended the abstract submission deadline to 7th September 2024 for the International Conference on Biotechnology and Biomedical Research! 🌱🔬 This is your chance to contribute to the future of science under the theme “Synergy in Diverse Disciplines: Shaping Future Perspectives.” Don't miss the opportunity to share your groundbreaking research with a global audience on 19th & 20th September 2024. Abstract Submission link: https://lnkd.in/gyvfrKtf Submit your abstracts today and join us in pushing the boundaries of biotechnology and biomedical research! 🚀📚 #biotechnology #biomedicalresearch #Bioleagues #scientificresearch #abstract #deadline #conference2024

SPONSORED: At the University of Cincinnati, research and innovation are at the forefront of what we do. The online drug development master’s degree provides an in-depth and formal education around drug development’s complex science and processes. The online pharmacogenomics and personalized healthcare master’s degree offers a unique opportunity for students to gain in-depth knowledge about Pharmacogenomics and understand the effects of genomics, environment, patient-specific factors on drug response, allowing for individualized therapy and optimal clinical outcomes. https://smpl.is/8mj9s

The speakers of RICT 2024 are announced! The programme will feature 19 plenary lectures and 6 short lectures focusing on "Interfacing Chemical Biology and Drug Discovery". TOPICS - Chemistry in Living Systems and Chemical Biology - Induced Proximity Including Degraders - Next Generation Cancer Therapeutics - New Modalities for Drug Discovery - Enabling Technologies - Recent Trends in Neurodegenerative Diseases Drug Development - First Disclosures of Clinical Candidates and Cases Studies - Breakthroughs in Deep Learning, CryoEM and their Impact on Drug Discovery Moreover, a special career session will be organised with industrial and academic participants. GRANTS A limited number of grants will be funded by the SCT and Corporate Sponsors with the aim to support the participation of young academic scientists. CALL FOR ABSTRACTS A poster session will provide the opportunity for all participants to present their current results. Abstract submission deadline:  May 14, 2024. Poster prizes will be attributed at the end of the meeting. CALL FOR AWARD APPLICATIONS 2 Prizes will be awarded by Galapagos and Evotec in partnership with the SCT. The 2 awardees will be invited to give a lecture during RICT 2024. Deadline for application submission: March 15, 2024 Visit www.rict2024.org for more information #MedChem #MedicinalChemistry #DrugDiscovery

Our paper detailing the SPARK program and why it is unique has been published in Nature Biotechnology! SPARK has broken into an underutilized space with a successful model to advance and de-risk therapeutic research in academia - by uniting with industry in a non-hierarchal community. Our paper provides more details on SPARK's goals, methods and metrics. #translationalresearch #drugdevelopment #academia https://lnkd.in/gSaD3Vdi